Table 1.
Clinicopathological charateristics
| Variable | Value (N) | ||
|---|---|---|---|
| Whole cohort | Post-menopausal | Pre-menopausal | |
| Age | |||
| Mean | 60.5 | 66.4 | 41.1 |
| Highest | 92 | 92 | 51 |
| Lowest | 34 | 49 | 34 |
| Grade | |||
| 1 | 8 (5.9%) | 4 (4.3%) | 2 (12.5%) |
| 2 | 69 (50.8%) | 50 (53.7%) | 4 (25.0%) |
| 3 | 59 (43.3%) | 39 (41.9%) | 10 (62.5%) |
| Tumour size (T) | |||
| 1 (<2 cm) | 63 (45.3%) | 47 (48.9%) | 4 (25.0%) |
| 2 (2–5 cm) | 70 (50.4%) | 47 (48.9%) | 10 (62.5%) |
| 3 (>5 cm) | 6 (4.3%) | 2 (2.1%) | 2 (12.5%) |
| Nodal spread (N) | |||
| 0 (no spread to lymph) | 77 (55.8%) | 54 (56.8%) | 9 (56.2%) |
| 1 (1–3 pos. lymph nodes) | 36 (26.1%) | 26 (27.3%) | 3 (18.75%) |
| 2 (4–9 pos. lymph nodes) | 14 (10.1%) | 11 (11.5%) | 1 (6.2%) |
| 3 (>10 pos. lymph nodes) | 11 (8.0%) | 4 (4.2%) | 3 (18.75) |
| Metastasis (M) | |||
| No Met | 137 (96.6%) | 93 (97.8%) | 16 (100%) |
| Mets | 2 (1.4%) | 2 (2.2%) | 0 (0%) |
| Menopausal status | |||
| Pre-menopausal | 16 (11.5%) | ||
| Post-menopausal | 96 (69.1%) | ||
| Unknown | 27 (19.4%) | Excluded | |
| BC subtype | |||
| HER2 | 37 (26.6%) | 26 (27.2%) | 6 (37.5%) |
| LUMA | 74 (53.2%) | 49 (51.0%) | 7 (43.7%) |
| LUMB | 11 (7.9%) | 8 (8.3%) | 0 (0%) |
| TNBC | 17 (12.2%) | 13 (13.5%) | 3 (18.75%) |
| Relapse (local and metastatic) | |||
| No | 94 (67.7%) | 64 (68.1%) | 11 (68.7%) |
| Yes | 45 (32.3%) | 30 (31.9%) | 5 (31.2%) |
| Relapse (metastatic) | |||
| No | 96 (69.1%) | 62 (66.7%) | 11 (68.7%) |
| Yes | 43 (30.9%) | 31 (33.3%) | 5 (31.2%) |
| Oestrogen receptor α | |||
| Negative | 36 (25.9%) | 26 (27.1%) | 5 (31.2%) |
| Positive | 103 (74.1%) | 70 (71.9%) | 11 (68.7%) |
| PGR | |||
| Negative | 74 (53.2%) | 53 (55.2%) | 7 (42.7%) |
| Positive | 65 (46.8%) | 43 (44.8%) | 9 (56.3%) |
| HER2 over-expression | |||
| No | 99 (71.2%) | 67 (69.8%) | 10 (62.5%) |
| Yes | 40 (28.8%) | 29 (30.2%) | 6 (37.5%) |
| STERSULF | |||
| Negative | 57 (41.3%) | 42 (44.2%) | 6 (37.5%) |
| Positive | 81 (58.7%) | 53 (55.8%) | 10 (62.5%) |
| Aromatase | |||
| Score 1–4 | 40 (28.2%) | 27 (38.6%) | 3 (30%) |
| Score 5–7 | 90 (71.2%) | 43 (61.4%) | 7 (70%) |
| 17βHSD Type 2 | |||
| Negative | 25 (18.1%) | 21 (22.1%) | 2 (12.5%) |
| Positive | 113 (81.9%) | 74 (77.9%) | 14 (87.5%) |
| ERβ1 | |||
| <150 H Score | 65 (46.7%) | 47 (49.0%) | 7 (43.7%) |
| >150 H score | 74 (53.2%) | 49 (51.0%) | 9 (56.3%) |
| AR | |||
| <10% | 18 (13.3%) | 12 (13.0%) | 1 (6.25%) |
| ≥10% | 117 (86.7%) | 80 (87.0%) | 15 (93.75%) |
| GR | |||
| <10% | 64 (48.5%) | 41 (45.1%) | 11 (73.3%) |
| ≥10% | 68 (51.5%) | 50 (54.1%) | 4 (26.6%) |
| FOXA1 | |||
| <10% | 0 (0%) | 0 (0%) | 0 (0%) |
| ≥10% | 132 (100% | 90 (100%) | 16 (100%) |
| KI67 | |||
| <15 | 31 (22.6%) | 21 (22.3%) | 2 (12.5%) |
| 15–30 | 37 (27.0%) | 26 (27.7%) | 2 (12.5%) |
| >30 | 69 (50.4%) | 47 (50%) | 12 (75.0%) |
Clinicopathological and histological characteristics of the cohort